MarginsXMarginsX
Home › Markets › Health Care › ACRS

Aclaris Therapeutics Inc. (ACRS)

ACRS trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$3.60
-8.04% on the day
Market cap
$571.8M
Small cap
Revenue · 2025
$7.8M
-58.2% on 2024
Net income · 2025
-$64.9M
-829.6% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1557746/000110465926020540/0001104659-26-020540-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerACRS on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2015
SEC CIK0001557746
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$7.8M
Net income-$64.9M
Operating income-$76.4M
Net margin-829.6%
Operating margin-975.9%
Revenue growth-58.2%
Cash$20.0M
Total assets$160.5M
P/E (computed)Net income was not positive
P/S (computed)73.1×

Warning signs

Cash runway
3.3 months
$20.4M cash at September 30, 2026
Share count, 1 year
+46.4%
2025-10-31 to 2026-10-30 · +123.9% over 3 years
Going-concern doubt
No
10-Q filed November 5, 2026
Insider net buying, 12 months
-$1.4M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.
"As of the report date, the Company does not believe that substantial doubt exists about its ability to continue as a going concern."
10-Q 2026-11-05
Cash and burn$20.4M cash; operating cash flow -$18.8M a quarter.Report 2026-09-30
Shares outstanding158,612,149 (2026-10-30); 108,345,239 a year earlier; 70,836,194 three years earlier.Cover page 2026-10-30
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the marketLatest 2026-10-27
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorPricewaterhouseCoopers LLP, Philadelphia, Pennsylvania, United StatesPCAOB Form AP 2026-03-09
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $1.4M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$1.5M-$18.5M-$24.1M$20.4MNo debt tags$6.4M10-Q 2026-11-05
Q2 2026
2026-06-30
$1.6M-$21.5M-$19.8M$19.2MNo debt tags$8.2M10-Q 2026-08-06
Q1 2026
2026-03-31
$2.0M-$19.8M-$18.1M$28.7MNo debt tags$8.4M10-Q 2026-05-07
Q4 2025
2025-12-31
$1.3M-$19.8M-$13.1M$20.0MNo debt tags$7.8M10-K 2026-02-26
Q3 2025
2025-09-30
$3.3M-$14.6M-$10.9M$25.3MNo debt tags$15.7M10-Q 2026-11-05
Q2 2025
2025-06-30
$1.8M-$15.4M-$10.0M$25.4MNo debt tags$16.8M10-Q 2026-08-06
Q1 2025
2025-03-31
$1.5M-$15.1M-$13.1M$30.4MNo debt tags$17.8M10-Q 2026-05-07
Q4 2024
2024-12-31
$9.2M-$96.6M-$8.9M$24.6MNo debt tags$18.7M10-K 2026-02-26

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-10-27
Latest annual report10-K2026-02-26
Latest quarterly / interim10-Q2026-11-05
Latest current report8-K2026-11-16
Latest proxyDEFA14A2026-04-23

Source: SEC EDGAR submissions feed, 874 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+0.5%
1 month+13.0%
3 months-33.1%
Year to date+30.2%
1 year+69.0%
From 52-week high-40.0%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
WVEWave Life Sciences Inc.$2.87-8.31%$566.0M
HELPHelus Pharma Inc.$7.67-13.53%$560.4M
CLYMClimb Bio Inc.$9.94-4.05%$583.9M
EVOEvotec SE$1.56-1.27%$555.0M
ZVRAZevra Therapeutics Inc.$9.25+1.87%$550.4M
AVBPArriVent BioPharma Inc.$11.56-11.15%$597.9M
GERNGeron Corporation$0.9419-2.60%$606.8M
INDPIndaptus Therapeutics Inc.$3.45+8.83%$529.9M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier